The Crossing Tool is an analytical instrument designed to examine how diagnostic technologies move from analytical performance into clinical deployment. It focuses on a specific structural transition: the crossing from controlled analytical environments into regulated, operational healthcare systems. This transition is not gradual. It is conditional.
The tool is used to explore the conditions under which a technology can:
- move from laboratory validation to clinical use
- operate within regulatory and evidence frameworks
- integrate into healthcare infrastructure
- sustain deployment at scale
In this context, performance is not sufficient.
The crossing depends on alignment across multiple structural dimensions.
What it does
The Crossing Tool does not evaluate technologies in isolation.
It evaluates whether the structural conditions required for deployment are present simultaneously
If these conditions do not align, the crossing fails — regardless of analytical performance.
How to use
The tool is applied through structured analysis within the Persodia repository.
Each application:
- examines a specific diagnostic context
- identifies the relevant structural constraints
- evaluates alignment across system layers
- interprets the likelihood and form of deployment
The Crossing Tool is not predictive in a deterministic sense.
It is interpretative. It clarifies conditions under which outcomes become possible.
Positioning
The Crossing Tool is not:
- a scoring model
- a benchmarking framework
- a consulting instrument
It is an analytical lens developed to interpret a recurring structural problem within the diagnostics industry.
Its purpose is to support understanding, not to prescribe action.
Access
This monograph is available without charge. All material published through the Persodia Research repository is made freely available. The authors retain full copyright. Material may be read, cited, and discussed freely, but may not be reproduced or repurposed without prior written permission.
Access to the full monograph requires a brief declaration of context and purpose — the authors wish to understand who engages with the material and in what context.
IVD Industry Monograph No. 1 — Structured Assessment
The Crossing Decision Tool
This tool applies the structural framework from Persodia Research Monograph No. 1. It assesses where your project currently stands in the crossing from analytical systems to clinical diagnostics — not where you plan to be, but where you are.
This tool does not score or rank projects relative to competitors. It applies a structural framework to self-reported conditions. It does not provide a roadmap, model financial outcomes, or substitute for regulatory, commercial, or financial advice.
Stage 0 of 3 — The Prior Question
Before the Crossing
“This is the question most projects skip. It is the most important one. Answer it based on the fundamental nature of your technology’s value — not your aspirations for it.”
Question 0 — Clinical Constraint Fit
Does your technology gain competitive advantage under clinical constraint — or does it lose it?
Clinical constraint means: fixed assay menu, standardised workflows, locked operating parameters, manufacturer accountability for every result, no flexibility to adapt rapidly to new applications. If your technology’s value depends on flexibility, application breadth, or speed of iteration — clinical constraint will reduce rather than enhance it.
Stage 1 of 3 — Product Foundation
Product Foundation
“Three conditions define whether a diagnostic offering exists. These are the requirements closest to analytical projects’ existing competence — and the stage where false confidence is most common.”
Condition 1a — System Completeness
Can the project field an integrated offering — instrumentation, reagents, software, LIS connectivity — validated as a whole, not as components?
Not planned. Not in development. Available now or within a defined, funded programme of 18 months or less.
Condition 1b — Assay Portfolio Viability
Does the project’s assay menu address at minimum three to five clinical questions across the patient pathway — with at least one assay that drives a treatment decision or defines a clinical standard?
A single analyte, regardless of analytical quality, does not constitute a viable portfolio for installed-base economics.
Condition 1c — Evidence Architecture
Has the project begun generating clinical validation evidence — not technical validation, but evidence that results change patient management — with a funded plan for post-market evidence generation beyond regulatory submission?
Stage 2 of 3 — Institutional Authorisation
Institutional Authorisation
“Two external gatekeeping processes convert a built product into a legally deployable and economically viable one. Both operate on timelines the project does not control. Both generate permanent obligations.”
Condition 2a — Regulatory Pathway Clarity
Does the project have a defined regulatory pathway — CE-IVD, FDA 510(k), PMA, or equivalent — with submission timelines based on actual regulatory interaction, not internal assumption? And has it built or contracted a QMS capable of sustaining post-market obligations permanently?
Condition 2b — Reimbursement Visibility
Has the project identified the specific reimbursement codes or pathways for its primary target markets, engaged with at least one payer or HTA body, and modelled fully-loaded cost recovery — including instrument placement amortisation, reagent supply, service, regulatory maintenance, and commercial infrastructure?
Stage 3 of 3 — Market Infrastructure
Market Infrastructure
“This is where most crossings fail. These requirements look, from the outside, like sales and logistics problems. They are structural commitments that must be in place before first system placement — not after scale.”
Condition 3a — Service and Supply Readiness
Can the project sustain reagent supply to clinical standards — cold chain, lot control, continuity guarantees — and field service at clinical urgency — geographic density, trained engineers, remote diagnostics, escalation protocols calibrated to clinical consequences — before first system placement?
Condition 3b — Customer Interface Capability
Does the project have IVD-competent commercial talent capable of managing multi-year tender processes, laboratory integration programmes, and clinical peer engagement? And can it sustain reagent rental economics — instruments placed below cost, revenue recovered over five to seven years — without pressure to generate hardware margin prematurely?
Full Assessment Report — Contact Details
One last step
Enter your details below. A secure, single-use link will be sent to your email address — valid for 24 hours.